Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2008

01-07-2008 | Gastrointestinal Oncology

Tumor Diameter as a Prognostic Factor in Patients with Gastric Cancer

Authors: Chikara Kunisaki, MD, PhD, Hirochika Makino, MD, PhD, Ryo Takagawa, MD, Takashi Oshima, MD, PhD, Yasuhiko Nagano, MD, PhD, Takashi Kosaka, MD, Hidetaka A. Ono, MD, PhD, Yuichi Otsuka, MD, PhD, Hirotoshi Akiyama, MD, PhD, Yasushi Ichikawa, MD, PhD, Hiroshi Shimada, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2008

Login to get access

Abstract

Background

The aim of this study was to evaluate the prognostic value of tumor diameter in gastric cancer.

Methods

The study group comprised a series of 1215 patients who underwent curative gastrectomy. The appropriate tumor diameter cutoff value was determined. Prognostic factors were evaluated by univariate and multivariate analyses.

Results

The tumor diameter cutoff value was 100 mm. Multivariate analysis showed that tumor site, macroscopic appearance, tumor diameter, depth of invasion, and presence of lymph node metastasis independently affected prognosis in all patients. Multivariate analysis of patients with larger tumors identified depth of invasion as an independent prognostic factor. A comparison between patients with smaller and larger tumors showed marked differences in the survival of those with stage II, IIIA, and IIIB tumors. A comparison of clinicopathological factors between stage II and III patients revealed that tumors occupying the entire stomach, ill-defined, undifferentiated, and serosa-penetrating tumors, and peritoneal metastases were far more frequent in patients with larger tumors.

Conclusions

Tumor diameter in gastric cancer is a reliable prognostic factor that might be a candidate for use in the staging system. To improve outcomes for patients with tumors ≥100 mm in diameter, it is necessary to establish therapeutic strategies for peritoneal metastasis, particularly in stage II and III tumors.
Literature
1.
Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458–68PubMedCrossRef
2.
Kim J, Sohn S, Chae Y, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007; 18:1030–6PubMedCrossRef
3.
Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007; 14:381–9PubMedCrossRef
4.
Griffiths EA, Pritchard SA, Valentine HR, et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007; 96:95–103PubMedCrossRef
5.
Aung PP, Oue N, Mitani Y, et al. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006; 25:2546–57PubMedCrossRef
6.
Kunisaki C, Shimada H, Nomura M, et al. Surgical outcome of serosa-negative advanced gastric carcinoma. Anticancer Res 2004; 24:3169–75PubMed
7.
Kunisaki C, Shimada H, Nomura M, et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer. Anticancer Res 2005; 25:1369–75PubMed
8.
Lee CC, Wu CW, Lo SS, et al. Survival predictors in patients with node-negative gastric carcinoma. J Gastroenterol Hepatol 2007; 22:1014–8PubMedCrossRef
9.
Park do J, Kong SH, Lee HJ, et al. Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery 2007; 141:757–63PubMedCrossRef
10.
Japanese Gastric Cancer Association. Japanese classification of gastric cancer, 2nd English ed. Gastric Cancer 1998; 1:8–24
11.
Sobin LH, Wittekind CH, eds. (2002) TNM: Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss
12.
Adachi Y, Oshiro T, Mori M, et al. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol 1997; 4:137–40PubMedCrossRef
13.
Shiraishi N, Sato K, Yasuda K, et al. Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007; 96:14–8PubMedCrossRef
14.
Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg 2006; 192:296–300PubMedCrossRef
15.
Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86:1455–62PubMedCrossRef
16.
Saito H, Tsujitani S, Oka S, et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 1999; 81:484–9PubMedCrossRef
17.
Moriguchi S, Kamakura T, Odaka T, et al. Clinical features of the differentiated and undifferentiated types of advanced gastric carcinoma: univariate and multivariate analyses. J Surg Oncol 1991; 48:202–6PubMedCrossRef
18.
Kunisaki C, Akiyama H, Nomura M, et al. Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res 2006; 26:639–46PubMed
Metadata
Title
Tumor Diameter as a Prognostic Factor in Patients with Gastric Cancer
Authors
Chikara Kunisaki, MD, PhD
Hirochika Makino, MD, PhD
Ryo Takagawa, MD
Takashi Oshima, MD, PhD
Yasuhiko Nagano, MD, PhD
Takashi Kosaka, MD
Hidetaka A. Ono, MD, PhD
Yuichi Otsuka, MD, PhD
Hirotoshi Akiyama, MD, PhD
Yasushi Ichikawa, MD, PhD
Hiroshi Shimada, MD, PhD
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9884-3

Other articles of this Issue 7/2008

Annals of Surgical Oncology 7/2008 Go to the issue

Healthcare Policy and Outcomes

Health-Related Quality of Life Outcomes in Disease-Free Survivors of Mid-Low Rectal Cancer After Curative Surgery

Endocrine Tumors

The Functional Impact on Voice of Sternothyroid Muscle Division During Thyroidectomy

Gastrointestinal Oncology

Squamous Cell Carcinoma of the Anal Canal: Utilization and Outcomes of Recommended Treatment in the United States

Healthcare Policy and Outcomes

Survival After Resection of Ampullary Carcinoma: A National Population-Based Study

Breast Oncology

A Prospective, Blinded Trial of Touch Prep Analysis versus Frozen Section for Intraoperative Evaluation of Sentinel Lymph Nodes in Breast Cancer

Gastrointestinal Oncology

The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric Adenocarcinoma